No biomarker

News alerts, weekly reports and conference planners

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval Bayer Press Release - 6 days (New B) darolutamide Sensitive : A1 Bayer Press Release - 6d	darolutamide Sensitive: A1 - Approval Bayer Press Release - 6 days darolutamide Sensitive : A1 Bayer Press Release - 6 days - (New B)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 6 days (New A1) pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 6d	pirtobrutinib Sensitive: A1 - Approval Eli Lilly Press Release - 6 days pirtobrutinib Sensitive : A1 Eli Lilly Press Release - 6 days - (New A1)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 1 week (New A1) pembrolizumab Sensitive : A1 FDA - 1wk	pembrolizumab Sensitive: A1 - Approval FDA - 1 week pembrolizumab Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week (New A2) lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1wk	lenalidomide + ixazomib Sensitive: A1 - Approval Oncology Central - 1 week lenalidomide + ixazomib Sensitive : A1 Oncology Central - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week (New A2) mosunetuzumab Sensitive : A1 NCCN - 1wk	mosunetuzumab Sensitive: A1 - Approval NCCN - 1 week mosunetuzumab Sensitive : A1 NCCN - 1 week - (New A2)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) acalabrutinib Sensitive : A2 NCCN - 1wk	acalabrutinib Sensitive: A2 - Guideline NCCN - 1 week acalabrutinib Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week (New A2) tazemetostat Sensitive : A2 NCCN - 1wk	tazemetostat Sensitive: A2 - Guideline NCCN - 1 week tazemetostat Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week (New B) pembrolizumab Sensitive : B Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : B Merck (MSD) Press Release - 1 week - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks (New B) bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2wk	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 2 weeks bevacizumab + atezolizumab Sensitive : A1 Businesswire - 2 weeks - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) sorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks sorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New B) fruquintinib Sensitive : A1 ASCO-GI 2023 - 2wk	fruquintinib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks fruquintinib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks (New A1) serplulimab Sensitive : A1 Henlius Press Release - 2wk	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks serplulimab Sensitive : A1 Henlius Press Release - 2 weeks - (New A1)
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks (New A1) penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2wk	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2 weeks - (New A1)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks (New B) toripalimab Sensitive : B BioSpace - 2wk	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks toripalimab Sensitive : B BioSpace - 2 weeks - (New B)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) Bv-AVE-PC Sensitive : A2 NCCN - 3wk	Bv-AVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks Bv-AVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) AEPA-CAPDAC Sensitive : A2 NCCN - 3wk	AEPA-CAPDAC Sensitive: A2 - Guideline NCCN - 3 weeks AEPA-CAPDAC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CVbP Sensitive : A2 NCCN - 3wk	CVbP Sensitive: A2 - Guideline NCCN - 3 weeks CVbP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) CHOP Sensitive : A2 NCCN - 3wk	CHOP Sensitive: A2 - Guideline NCCN - 3 weeks CHOP Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OEPA Sensitive : A2 NCCN - 3wk	OEPA Sensitive: A2 - Guideline NCCN - 3 weeks OEPA Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) ABVE-PC Sensitive : A2 NCCN - 3wk	ABVE-PC Sensitive: A2 - Guideline NCCN - 3 weeks ABVE-PC Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks (New B) RG6026 Sensitive : B Roche Press Release - 3wk	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks RG6026 Sensitive : B Roche Press Release - 3 weeks - (New B)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1	docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1

No biomarker

Associations